New melanoma trial initiated at Moffitt Cancer Center to investigate utility of immunotherapy biomarkers

Phase I melanoma patient trial will test whether the drug PV-10 works better in patients with a distinct immune biomarker signature in both blood and tumor tissue.

Circulating tumor cells may be predictive for recurrence and survival in melanoma patients

Circulating tumor cells detected in the blood of stage III melanoma patients may be a predictive blood biomarker helpful for deciding which patients could benefit from aggressive adjuvant therapy.

How necessary is a sentinel node biopsy for melanoma?

A new report weighs the pros and cons of a sentinel node biopsy for melanoma patients.

National Cancer Institute Report shows cancer death rates dropping for most but not all cancers

The Annual Report on the status of cancer shows a decline in cancer deaths from major cancers including lung, colorectal, prostate, and breast, but some cancer deaths continue to increase specifically for men with melanoma as well as for those with liver, uterine, and pancreatic cancers.

‘‘Intermittent dosing’ strategy for BRAF inhibitor treatment holds promise for advanced melanoma

In an industry-academia collaboration, researchers have found an intermittent dose of vemurafenib, an oral BRAF inhibitor used to treat metastatic melanoma can help delay resistance in a mouse model. The results have implications for patients taking the drug.

Mutation Linked to Better Outcomes For Uveal Melanoma Patients

Researchers at Washington University found mutations in the gene SF3B1 are associated with a type of uveal melanoma that has better outcomes and is less likely to spread to other parts of the body.

Sorafenib does not improve survival in metastatic melanoma Phase III Trial Shows

Sorafenib plus chemotherapy did not improve the overall survival of metastatic melanoma patients not previously treated with chemotherapy. The trial results are published in the Journal of Clinical Oncology.

Smartphone Applications for Melanoma Diagnosis Are Not All Ready for Primetime

Researchers assessed latest apps that claim to help diagnose questionable moles as melanoma. The performance of the apps is highlight variable- 3 of 4 apps incorrectly classified one-third of melanomas as “not concerning”.

New Driver Mutations of Malignant Melanoma Discovered

Researchers at the Dana-Farber and Broad Institute in Boston identified 2 mutations that collectively occur in 71 percent of malignant melanoma tumors making them more common than the BRAF mutation. These highly “recurrent” mutations may be the most common mutations in melanoma cells found to date. The mutations are located in non-protein-coding DNA that regulates the activity of genes, both located in the promoter region of TERT, the telomerase enzyme